Psychotic Disorders Clinical Trial
Official title:
Dutch Prediction of Psychosis Study
The Dutch Prediction of Psychosis Study (DUPS) is a prospective study of predictors of the
transition to psychosis in help-seeking adolescents at high risk for developing a first
psychotic episode. The aim of the project is supplemented by a systematic account of the
pathways to care, the disabilities and needs and the therapeutic interventions that are
currently used in this population.
Multi-level assessment includes behavioral and cognitive variables as well as structural
brain imaging and neurophysiological data. Subjects will be followed up at regular intervals
during (at least) two years to monitor the development of their (psychotic) symptoms. This
will allow us to analyze the predictive validity of the variables.
The Dutch Prediction of Psychosis Study (DUPS) is a collaboration of the Academic Medical
Center in Amsterdam (AMC) and the University Medical Center in Utrecht (UMC). The main
objectives are:
1. Pathways to care: the description of the ways subjects at risk for psychosis get access
to the health care system and the detection of obstacles to adequate treatment
2. Prediction: the systematic multi-level assessment of predictors of the transition to a
first psychotic episode in subjects at risk for psychosis
3. Disability: the description of disabilities, deficits and needs in prodromal
individuals
4. Intervention: the description of the therapeutic and preventive interventions applied
to prodromal individuals
While the same fundamental principles (e.g. inclusion criteria) are applied in both centers,
additional instruments or paradigms are added in the separate centers according to specific
interests, expertise and setting.
Our specific interest is in the social cognition and social functioning of prepsychotic
individuals. Therefore, in addition to the subjects that are at high risk for psychosis
according to the DUPS inclusion/exclusion criteria we are including another group of
subjects that is at elevated risk for psychosis, namely subjects who have a Multiple Complex
Developmental Disorder (MCDD) which is a subtype of the pervasive developmental disorders.
The study is a prospective longitudinal field-study with repeated measures to monitor
subjects at high risk for psychosis.
The study sample in the UMC consists of adolescents who are already referred to adolescent
psychiatric outpatient's clinics because of mental problems. After informed consent they are
screened for the following inclusion and exclusion criteria:
1. Age between 12 and 18 years
2. No previous psychotic episode for more than one week
3. Verbal IQ above 75
4. Symptoms are not due to an organic mental disorder or substance abuse
5. Belong to one or more of the following groups:
1. Basic symptoms: presence of self-perceived cognitive thought disturbances
2. Familial risk plus reduced functioning: having a first- or second degree relative
with a history of any psychotic disorder in combination with a deterioration of
mental state and/or social functioning in the last year
3. Attenuated psychotic symptoms: presence of psychotic symptoms at sub-clinical
level
4. Brief, limited or intermittent psychotic symptoms: having a history of psychotic
symptoms with a duration of less than one week and spontaneous remission
5. Multiple Complex Developmental Disorder
Assessment includes:
1. basic clinical assessment
2. neuropsychological measures (attention, memory, executive functioning)
3. social cognitive measures (facial emotion recognition, mentalizing, social attribution)
4. measures of social cognition and behavior
5. EEG and Event Related Potentials (including smooth pursuit eye movement, auditory
mismatch negativity)
6. structural MRI
Some data will be collected retrospectively upon inclusion into the study, for example
symptom history and pathways to care. Outcome is assessed after 9, 18 and 24 months.
;
Observational Model: Defined Population, Time Perspective: Longitudinal
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Terminated |
NCT03230097 -
This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
|
Phase 2 | |
Completed |
NCT03497663 -
VIA Family - Family Based Early Intervention Versus Treatment as Usual
|
N/A | |
Active, not recruiting |
NCT05726617 -
Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders
|
N/A | |
Not yet recruiting |
NCT03807388 -
ReMindCare App for Patients From First Episode of Psychosis Unit.
|
N/A | |
Recruiting |
NCT02874573 -
Tocilizumab in Schizophrenia
|
Phase 1 | |
Terminated |
NCT02584114 -
Brain Effects of Memory Training in Early Psychosis
|
N/A | |
Completed |
NCT02906553 -
The Role of Nitric Oxide in Cognition in Schizophrenia
|
N/A | |
Completed |
NCT01981356 -
Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis
|
Phase 0 | |
Terminated |
NCT02841956 -
Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement
|
N/A | |
Withdrawn |
NCT02213887 -
Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
|
Phase 4 | |
Recruiting |
NCT02009969 -
Serial Comparisons of Abdominal and Neurological MRI Scans
|
N/A | |
Recruiting |
NCT02848469 -
Irish Omega-3 Study
|
Phase 2 | |
Completed |
NCT02648321 -
Motivational Intervention for Physical Activity in Psychosis
|
N/A | |
Enrolling by invitation |
NCT00762866 -
Psychiatric Genotype/Phenotype Project Repository
|
||
Completed |
NCT00484302 -
Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis
|
N/A | |
Completed |
NCT00130923 -
Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
|
Phase 4 | |
Completed |
NCT00844922 -
Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)
|
Phase 2 | |
Completed |
NCT00455234 -
Rapid Tranquillization Trial: TREC-India II
|
Phase 3 | |
Completed |
NCT00253240 -
Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population
|